{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:18:15Z","timestamp":1793351895088,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,14]],"date-time":"2027-01-14T00:00:00Z","timestamp":1799884800000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["R01 HD117940"],"award-info":[{"award-number":["R01 HD117940"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005227Y5123"],"award-info":[{"award-number":["005227Y5123"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011221","name":"The University of Alabama at Birmingham Department of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011104","name":"Universitat Aut\u00f2noma de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD117940"],"award-info":[{"award-number":["R01 HD117940"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["K23 159331"],"award-info":[{"award-number":["K23 159331"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcf.2025.11.013","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:10:59Z","timestamp":1764306659000},"page":"28-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic assessment of elexacaftor\/tezacaftor\/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother\/affected fetus dyad"],"prefix":"10.1016","volume":"25","author":[{"given":"Rachel G.","family":"Sinkey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-0946","authenticated-orcid":false,"given":"Christopher Miles","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-6768","authenticated-orcid":false,"given":"Stefanie","family":"Krick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-3495","authenticated-orcid":false,"given":"Kevin J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0514-8536","authenticated-orcid":false,"given":"Jennifer S.","family":"Guimbellot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.11.013_bib0001","series-title":"2023 Annual data report","year":"2024"},{"key":"10.1016\/j.jcf.2025.11.013_bib0002","series-title":"2024 Patient registry highlights","year":"2025"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.013_bib0003","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcf.2025.03.009","article-title":"First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: report from the MODUL-CF study","volume":"24","author":"Bonnel","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.013_bib0004","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcf.2024.11.011","article-title":"Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis","volume":"24","author":"Metcalf","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.013_bib0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal Cystic Fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of Cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.013_bib0006","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.013_bib0007","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.013_bib0008","first-page":"47","article-title":"Pregnancy in people with cystic fibrosis treated with highly effective modulator therapy","volume":"145","author":"Goralski","year":"2025","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jcf.2025.11.013_bib0009","article-title":"Pregnancy in patients with cystic fibrosis","author":"Pineles","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.013_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.chc.2014.09.005","article-title":"Maternal medication, drug use, and breastfeeding","volume":"24","author":"Rowe","year":"2015","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.jcf.2025.11.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123518","article-title":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","volume":"1213","author":"Ryan","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.013_bib0012","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jcf.2025.03.010","article-title":"Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant","volume":"24","author":"Guimbellot","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.013_bib0013","unstructured":"Anderson P.O. Modeling drug passage into Breastmilk. Presented at: U.S. Food and Drug Administration Drug Information Presentation Series; 2016; Silver Spring, MD. Accessed October 5, 2025. https:\/\/www.fda.gov\/files\/drugs\/published\/Modeling-Drug-Passage-into-Breastmilk.pdf."},{"key":"10.1016\/j.jcf.2025.11.013_bib0014","unstructured":"P67L\/F508del. CFTR2. Updated September 25, 2024. Accessed June 19, 2025. https:\/\/cftr2.org\/mutation\/scientific\/P67L\/F508del."},{"issue":"10","key":"10.1016\/j.jcf.2025.11.013_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105242","article-title":"Elexacaftor\/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics","volume":"299","author":"Kim","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jcf.2025.11.013_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2024.102314","article-title":"Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia","volume":"86","author":"Liu","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jcf.2025.11.013_bib0017","unstructured":"Trikafta (elexacaftor, tezacaftor, and ivacaftor). Package Insert. Vertex Pharmaceuticals, Inc., Jan. 2021. Accessed 19 June 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf."},{"issue":"5","key":"10.1016\/j.jcf.2025.11.013_bib0018","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","article-title":"Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies","volume":"23","author":"Kowalik","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.013_bib0019","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2025.03.006","article-title":"CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: insights from an unsuccessful case","volume":"24","author":"Destoop","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.013_bib0020","article-title":"Fetal drug exposure after maternally administered CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor in a rat model","volume":"54","author":"Li","year":"2024","journal-title":"Infect Dis Now"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.013_bib0021","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.11.013_bib0022","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40262-025-01507-2","article-title":"Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: a systematic review","volume":"64","author":"Elzinga","year":"2025","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.013_bib0023","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:15:14Z","timestamp":1778620514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1569199325025287"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic assessment of elexacaftor\/tezacaftor\/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother\/affected fetus dyad","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}